BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that Dr. Brian Caveney, chief medical officer and president of Labcorp Diagnostics, was recognized by Modern Healthcare as one of the 100 most influential people in healthcare in 2020.
According to Modern Healthcare, editors of the publication and its readers selected the most innovative and resilient candidates who influenced the course that healthcare took during a global crisis and used current events as an inspiration to do better.
“I am extremely proud of Labcorp’s diagnostics and drug development teams who have worked day and night to address the COVID-19 pandemic through science, collaboration, and innovation,” said Dr. Caveney. “Since becoming the first commercial lab to launch a COVID-19 PCR test in March, Labcorp has increased testing capacity, created multiple testing options and worked closely with clinical research partners on vaccines and therapies. I am honored to be recognized by Modern Healthcare, but I could not have done it without my amazing colleagues who have worked tirelessly throughout the year to address the healthcare crisis.”
Dr. Caveney joined Labcorp after serving as chief medical officer of Blue Cross and Blue Shield of North Carolina (Blue Cross NC). He also served as chief clinical officer of Mosaic Health Solutions, a wholly owned subsidiary of Blue Cross NC for strategic investments in diversified health solutions. Prior to Blue Cross NC, Dr. Caveney was a practicing physician. He is currently an assistant professor at Duke University Medical Center.
In June 2020, Dr. Caveney was recognized by Modern Healthcare as one of this year’s 50 Most Influential Clinical Executives.
The complete ranking is featured in the December 7 issue of Modern Healthcare, and profiles of the honorees are available at ModernHealthcare.com/100MostInfluential.
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and save lives. With over 70,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $11.5 billion in FY2019. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to clinical laboratory testing and the potential benefits of a COVID-19 test home collection kit and our responses to and the expected future impacts of the COVID-19 pandemic and the opportunities for future growth. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, whether our response to the COVID-19 pandemic will prove effective, the impact of the COVID-19 pandemic on our business and financial condition, as well as on general economic, business, and market conditions, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, the Company’s satisfaction of regulatory and other requirements, patient safety issues, changes in testing guidelines or recommendations, federal, state, and local governmental responses to the COVID-19 pandemic, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, and employee relations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.